Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 29 日召开第二届董事会第八次会议，并于 2024 年 9 月 20 日召开 2024 年第一次临时股东大会审议通过了《关于回购公司股份方案的议案》，同意 公司使用自有资金以集中竞价交易方式回购公司部分已发行的人民币普通股股 份，用于注销并相应减少公司注册资本。本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回购价格不超过人民币 50.00 元 /股（含），回购实施期限为自公司股东大会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 8 月 30 日、2024 年 9 月 20 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编 号：2024-026）和《回购报告书》（公告编号：2024-030）。 公司于 2025 年 6 月 24 日召开第二届董事会第十九次会议，审议通过了 《关于调整回购股份价格上限的议案》，同意公司将回购价格上限调整为 80.00 元/股（含）。调整后的回购股份价格上限自 ...

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1: Financial Performance - In 2024, the company achieved a revenue of 645.02 million yuan, representing a year-on-year growth of 18.65% [1] - The net profit attributable to shareholders for 2024 was 123.83 million yuan [1] - In Q1 2025, the company reported a revenue of 186.49 million yuan, with a year-on-year increase of 27.73% [1] - The net profit attributable to shareholders in Q1 2025 was 40.58 million yuan, reflecting a growth of 32.30% [1] Group 2: Strategic Focus and Market Position - The company is concentrating on biopharmaceuticals and cell immunotherapy, driving core business development and global strategy [1] - There is a continuous increase in demand for biological reagents such as recombinant proteins, driven by the recovery of the innovative drug market [2] - The company aims to enhance its leadership and competitive advantage in the industry through improved technology and product development [2] Group 3: Product Development in CGT and ADC - The company provides comprehensive solutions for cell and gene therapy (CGT), addressing challenges in R&D technology, product quality, and supply chain stability [3] - Over 50 high-quality GMP-grade products have been developed, including cytokines and antibodies for CGT applications [5] - In the ADC field, the company focuses on five core elements: suitable antigen targets, highly specific antibodies, effective toxin molecules, quality linkers, and precise Drug Antibody Ratio (DAR) [6][7]

Core Viewpoint - The company, 百普赛斯, is focusing on the biopharmaceutical and cell immunotherapy sectors, aiming for global expansion and enhancing its competitive edge through innovation and optimized management practices. Financial Performance - In 2024, the company achieved a revenue of 645.02 million yuan, representing an 18.65% year-on-year increase, with net profit attributable to shareholders reaching 123.83 million yuan [1] - For Q1 2025, the company reported a revenue of 186.49 million yuan, a 27.73% increase year-on-year, and a net profit of 40.58 million yuan, up 32.30% [2] Market Trends and Opportunities - The company benefits from supportive national policies and an active market for innovative drugs, focusing on antibody drugs, cell and gene therapy (CGT), and antibody-drug conjugates (ADC) [3] - The demand for biological reagents, particularly recombinant proteins, is expected to grow, providing more business opportunities for the company [3] Global Operations - The company has established a logistics system in China, the US, Switzerland, and South Korea, enabling comprehensive market coverage and efficient response to customer needs [4] - It has successfully built a talent pool with international perspectives to support its global operations, covering nearly 80 countries and regions [4] CGT Sector Development - The company is well-positioned in the CGT field, offering comprehensive solutions from drug target discovery to commercial production, leveraging its extensive protein pipeline and technical expertise [5] - It has developed over 50 high-quality GMP-grade products for cell and gene therapy applications, enhancing its service offerings [6][7] ADC Sector Development - The company is actively expanding its product and service offerings in the ADC field, which combines targeted antibodies with potent chemotherapy agents, addressing the growing demand for innovative cancer treatments [8][9] Neuroscience Sector Development - The company is focusing on brain-related diseases, providing high-quality recombinant proteins and neurotrophic factors to support research and treatment development for conditions like Alzheimer's and Parkinson's diseases [10]

Financial Performance - In 2024, the company achieved a revenue of 645.02 million CNY, a year-on-year increase of 18.65%, with overseas revenue (excluding specific acute respiratory disease-related products) growing over 20% [1] - For Q1 2025, the company reported a revenue of 186.49 million CNY, reflecting a year-on-year growth of 27.73%, and a net profit of 40.58 million CNY, up 32.30% [1] Business Strategy - The company focuses on biomedicine and cell immunotherapy, emphasizing a market-oriented, customer-first, and innovation-driven R&D approach [1] - A comprehensive internal management optimization has been implemented to enhance the marketing network and overall competitiveness [1] Global Operations - The company has established a logistics system covering nearly 80 countries and regions, serving over 10,000 industrial and research clients [3] - A robust internal communication mechanism supports seamless collaboration across global branches [3] Cell and Gene Therapy (CGT) - The company offers comprehensive solutions for CGT, leveraging its extensive protein pipeline and technical expertise [4] - Over 50 high-quality GMP-grade products have been developed, supporting clinical research and commercial production [6] Antibody-Drug Conjugates (ADC) - ADCs are highlighted as a key focus area, combining targeted antibodies with potent chemotherapy agents to enhance treatment efficacy while minimizing side effects [7] - The company provides a range of products and services for ADC development, covering the entire process from antibody preparation to quality control [8] Neuroscience Research - The company is actively involved in neuroscience, providing high-quality recombinant proteins and pre-formed fibrils (PFFs) for research on neurodegenerative diseases [9] - Products developed for Alzheimer's, Parkinson's, and Huntington's diseases support both treatment and diagnostic research [9]

北京百普赛斯生物科技股份有限公司 第二届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301080 证券简称：百普赛斯 公告编号：2025-041 一、监事会会议召开情况 北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届监事会第十 八次会议于 2025 年 6 月 24 日上午 9:00 在北京市北京经济技术开发区宏达北路 8 号公司会议室以通讯表决和现场表决的方式召开。本次会议通知及会议资料于 2025 年 6 月 23 日以专人送达、传真、电子邮件的方式发出，本次会议为紧急会 议，根据《公司章程》的有关规定，公司全体监事均同意豁免本次监事会会议的 通知时限要求。会议应出席监事 3 人，参与现场会议的监事 2 人，参与通讯会议 的监事 1 人，屈文婷女士以通讯方式出席。本次会议由监事会主席屈文婷女士主 持，会议的召集、召开符合法律、法规、规则和《公司章程》规定。 二、监事会会议审议情况 参会的监事一致同意通过如下决议： 审议通过《关于作废部分已授予但尚未归属的限制性股票的议案》 经审核，监事会认为： 根据《上 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-043 一、回购股份的基本情况 公司于 2024 年 8 月 29 日召开第二届董事会第八次会议，并于 2024 年 9 月 20 日召开 2024 年第一次临时股东大会审议通过了《关于回购公司股份方案的议 案》，同意公司使用自有资金以集中竞价交易方式回购公司部分已发行的人民币 普通股股份，用于注销并相应减少公司注册资本。本次回购资金总额不低于人民 币 2,000 万元（含）且不超过人民币 4,000 万元（含），回购价格不超过人民币 50.00 元/股（含），回购实施期限为自公司股东大会审议通过本次回购股份方案 之日起 12 个月内。具体内容详见公司分别于 2024 年 8 月 30 日、2024 年 9 月 20 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》 （公告编号：2024-026）和《回购报告书》（公告编号：2024-030）。 关于调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、为保障回购股份 ...

二〇二五年六月 深圳市他山企业管理咨询有限公司 关于北京百普赛斯生物科技股份有限公司 2022 年限制性股票激励计划 作废部分限制性股票事项的 独立财务顾问报告 | 释 义 2 | | --- | | 声 明 3 | | 一、本激励计划已履行的审批程序 4 | | 二、本次限制性股票作废情况 6 | | 三、独立财务顾问意见 7 | | 四、备查文件及备查地点 8 | 深圳市他山企业管理咨询有限公司 独立财务顾问报告 释 义 在本报告中，除非上下文文意另有所指，下列词语具有如下含义： | 百普赛斯、上市公司、公司 | 指 | 北京百普赛斯生物科技股份有限公司（证券简称：百 | | --- | --- | --- | | | | 普赛斯；证券代码：301080） | | 本激励计划、股权激励计划 | 指 | 北京百普赛斯生物科技股份有限公司 2022 年限制性 | | | | 股票激励计划 | | 《激励计划（草案）》、本激 | 指 | 《北京百普赛斯生物科技股份有限公司 2022 年限制 | | 励计划草案 | | 性股票激励计划（草案）》 | | 独立财务顾问报告、本报告 | 指 | 深圳市他山企业管理咨询 ...

SHANGHAI IQE ONE III IIA ZUI 68 Yin Chena Road Middle hanghai 200120 P.R.China 上海市通力律师事务所 关于北京百普赛斯生物科技股份有限公司 2022 年限制性股票激励计划作废部分已授予尚未归属的 限制性股票相关事项之法律意见书 致:北京百普赛斯生物科技股份有限公司 敬启者: 伦敦 LONDON 22BJ3110012/SH/wg/cm/D6 上海 SHANGHAI 上海市通力律师事务所(以下简称"本所")受北京百普赛斯生物科技股份有限公司(以下 简称"公司")委托. 指派朱晓明律师、黄雅程律师(以下合称"本所律师")作为公司特聘专 项法律顾问,就公司 2022 年限制性股票激励计划(以下简称"本次激励计划")作废部分已 授予尚未归属的限制性股票(以下简称"本次作废")相关事项,根据《中华人民共和国公司 法》、《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》(以 下简称"《管理办法》")、《深圳证券交易所创业板股票上市规则》(以下简称"《上市规则》") 和《深圳证券交易所创业板上市公司自律监管指南第１号 ...